Laura Shawver Sells 26,520 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) Director Laura Shawver sold 26,520 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $6.72, for a total value of $178,214.40. Following the sale, the director now owns 210,346 shares in the company, valued at approximately $1,413,525.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Laura Shawver also recently made the following trade(s):

Get ARS Pharmaceuticals alerts:

• On Thursday, July 6th, Laura Shawver sold 33,510 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $6.34, for a total value of $212,453.40.
• On Thursday, June 1st, Laura Shawver sold 73,059 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $6.80, for a total value of $496,801.20.
• On Tuesday, May 9th, Laura Shawver sold 42,900 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $5.31, for a total value of $227,799.00.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY opened at $6.13 on Friday. The stock’s 50-day moving average is $6.78 and its two-hundred day moving average is $7.21. ARS Pharmaceuticals, Inc. has a 1-year low of $3.68 and a 1-year high of $9.65.

ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) last released its quarterly earnings data on Monday, May 15th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. The business had revenue of $0.02 million during the quarter. Sell-side analysts expect that ARS Pharmaceuticals, Inc. will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SPRY. Squarepoint Ops LLC purchased a new position in shares of ARS Pharmaceuticals in the 1st quarter valued at about $84,000. Prelude Capital Management LLC purchased a new position in shares of ARS Pharmaceuticals in the 1st quarter valued at about $98,000. State Street Corp increased its holdings in shares of ARS Pharmaceuticals by 50.4% in the 1st quarter. State Street Corp now owns 129,191 shares of the company’s stock valued at $841,000 after acquiring an additional 43,300 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of ARS Pharmaceuticals in the 1st quarter valued at about $895,000. Finally, Ameriprise Financial Inc. purchased a new position in shares of ARS Pharmaceuticals in the 1st quarter valued at about $1,825,000. Hedge funds and other institutional investors own 56.12% of the company’s stock.

About ARS Pharmaceuticals

(Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis.

See Also

• Five stocks we like better than ARS Pharmaceuticals
• Pfizer Just Invested $25 million In This Biotech
• Cracks In The Labor Market? Not Yet, But They’re Coming 
• Levi’s: Buy On The Dip Or Downtrend In Play? 
• Who Wins And Who Loses With China’s Metal Restrictions
• 3 Large Semiconductor Makers Offering Dividends & Price Growth

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.